Prot #AMV564-301: A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Project: Research project

Project Details

StatusActive
Effective start/end date7/15/207/15/23

Funding

  • Amphivena Therapeutics, Inc. (Prot #AMV564-301)